Prostate Cancer Clinical Trial
— CONTROL4LIFEOfficial title:
Continence, Sexual and Metabolic Health Programming to Promote Prostate Cancer Wellness for Life (CONTROL4LIFE)
The Continence, Sexual and Metabolic Health (CONTROL 4 LIFE) study will evaluate the recovery of continence, sexual function, and health outcomes in individuals who have undergone surgery for prostate cancer. The purpose of this study is to better understand the timelines of recovery for these outcomes after surgery for prostate cancer. As part of this study, all participants will receive resources offered by Alberta Health Services regarding pre- and post-prostatectomy care, including information on pelvic floor exercises. Through the CONTROL 4 LIFE study, the investigators will also be evaluating outcomes related to physical activity, fitness and quality of life. These assessments will enable the investigators to better understand how well and how long it takes for individuals to recover after surgery for prostate cancer.
Status | Recruiting |
Enrollment | 106 |
Est. completion date | June 30, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - have a diagnosis of prostate cancer (stage I to IV); - be scheduled for a prostatectomy surgery (any surgical approach); - have no restriction to participate in at least mild levels of physical activity, as confirmed by the Physical Activity Readiness Questionnaire (PAR-Q+); - speak and understand English. - adult: 18 years of age or older - optional exercise component: willing and able to commit to the 12-week intervention Exclusion Criteria: - have any medical conditions that may interfere with continence (i.e. neurological diseases); - have any contraindications to exercise testing or training; - have recent (>6 months) modifications to any medication aiming to reduce urinary incontinence (i.e. Myrbetric); - do not have regular access to the internet and a smart device or a computer at home/ at their community center; - are already receiving a pelvic floor exercise program through a pelvic floor physical therapist from their community. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Completion Rate | The number of participants completing the study including all planned outcomes | Final assessment at one year | |
Secondary | Recruitment rate | Percentage of participants who are eligible and agree to participate | One year | |
Secondary | Adherence rate | Adherence to the intervention components | Post-intervention: 12 weeks | |
Secondary | 24-hour pad test | Mean: Individual's urine loss by measuring weight (grams) of an absorbent pad | 24 hours at two time points: immediate post surgery and 12 weeks | |
Secondary | Expanded Prostate Cancer Index Composite for Clinical Practice | 16-questions: urinary function, sexual and erectile function, bowel and hormonal function; Scores: 0 (no symptoms) to 60 (most severe symptoms); Higher scores indicate worse functioning | One-year | |
Secondary | International Consultation on Incontinence Questionnaire | 13 questions: occurrence and bother of lower urinary tract symptoms, quality of life; Range of scores: 0-20 voiding subscale; 0-20 incontinence symptoms; Higher scores indicate worse functioning | One-year | |
Secondary | 36-Item Short Form Survey | Quality of life measure: Items are scored 0-100 (percentage of total possible score): Higher scores equal better quality of life | One-year | |
Secondary | Edmonton Symptom Assessment Scale | 11-item ordinal scale; Range 0-60; with higher scores indicating higher symptom burden | One year | |
Secondary | Self-efficacy Questionnaire: Incontinence | 6 item ordinal scale: Range 0-60; Higher scores indicating higher self-efficacy | One year | |
Secondary | Grip Strength | Dyanometer: mean in kgs | 12 weeks | |
Secondary | Lower body strength | Sit-to-stand: mean number completed in 30 seconds | 12-weeks | |
Secondary | Upper limb mobility | Shoulder Range of Motion: mean value in degrees | 12 weeks | |
Secondary | Flexibility | Sit and reach: mean value in cm | 12-weeks | |
Secondary | Balance | One-leg stance test: mean time in seconds | 12-weeks | |
Secondary | Walking endurance | Six-minute walk test: mean distance in metres | 12-weeks | |
Secondary | Body Mass Index | Height and weight will be combined to calculate BMI: mean: weight in kilograms divided by height in metres squared | 12-weeks | |
Secondary | Glucose | mmol/L (mean value) | 12-weeks | |
Secondary | Insulin level | mmol/L (mean value) | 12-weeks | |
Secondary | Lipid profile | Cholesterol level: mg/dL (mean value) | 12-weeks | |
Secondary | Hemoglobin A1c | Value in percentage (mean value) | 12-weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |